These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26405998)

  • 1. Discrete virus infection model of hepatitis B virus.
    Zhang P; Min L; Pian J
    Biomed Mater Eng; 2015; 26 Suppl 1():S2187-95. PubMed ID: 26405998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus kinetics and mathematical modeling.
    Perelson AS; Ribeiro RM
    Semin Liver Dis; 2004; 24 Suppl 1():11-6. PubMed ID: 15192796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
    Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
    Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
    Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
    Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
    Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
    Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
    Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication].
    Song JW; Zhang G; Lin JG; Tang WX; Lin JS
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):593-6. PubMed ID: 15504288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.
    Moses SE; Lim Z; Zuckerman MA
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):891-9. PubMed ID: 21973301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
    Herreros de Tejada Echanojáuregui A; Moreno Planas JM; Rubio González E; Portero Azorin F; López Monclús J; Revilla Negro J; Lucena de la Poza JL; Sánchez Turrión V; Barrios Peinado C; Cuervas-Mons Martínez V
    Transplant Proc; 2005 Apr; 37(3):1507-8. PubMed ID: 15866657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy.
    Kazim SN; Wakil SM; Khan LA; Hasnain SE; Sarin SK
    Lancet; 2002 Apr; 359(9316):1488-9. PubMed ID: 11988251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B].
    Li GY; Sheng JL; Huang HJ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):133-5. PubMed ID: 18574538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F
    Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.